Hexima Limited (HXL.AX)
- Previous Close
0.0130 - Open
0.0130 - Bid 0.0110 x 6000000
- Ask 0.0130 x 4425900
- Day's Range
0.0130 - 0.0130 - 52 Week Range
0.0100 - 0.0240 - Volume
761,801 - Avg. Volume
154,197 - Market Cap (intraday)
2.172M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company's lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.
hexima.com.auRecent News: HXL.AX
Performance Overview: HXL.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HXL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HXL.AX
Valuation Measures
Market Cap
2.17M
Enterprise Value
258.56k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.32%
Return on Equity (ttm)
-26.54%
Revenue (ttm)
193.86k
Net Income Avi to Common (ttm)
-753.18k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-486.14k
Company Insights: HXL.AX
HXL.AX does not have Company Insights